Reaction
Malignant Melanoma In Situ reporting signals
As of the last recalculation, Malignant Melanoma In Situ appears in 1,244 FAERS reports alongside 33 co-occurring drug terms. The strongest observed disproportionality signal is ACETYLCYSTEINE (PRR 161.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Acetylcysteine | 85 | 161.9 | 163.4 |
| Ciclesonide | 86 | 113.4 | 114.1 |
| Sildenafil Citrate | 391 | 74.5 | 74.7 |
| Tadalafil | 278 | 59.5 | 59.7 |
| Tamsulosin Hydrochloride | 56 | 48.0 | 48.2 |
| Doxyclycline Hyclate | 35 | 35.4 | 35.4 |
| Azithromycin | 70 | 30.8 | 30.8 |
| Azithromycin Monohydrate | 70 | 29.7 | 29.8 |
| Melatonin | 88 | 29.0 | 29.1 |
| Naproxen Sodium Tablet, Coated | 23 | 28.9 | 29.0 |
| Naproxen Sodium, Coated Tablets | 23 | 28.9 | 29.0 |
| Naproxen Sodium 220Mg | 23 | 28.9 | 28.9 |
| Vemurafenib | 18 | 25.4 | 25.4 |
| Levofloxacin | 82 | 24.3 | 24.3 |
| Levofloxacin In 5% Dextrose | 82 | 24.3 | 24.3 |
| Doxycycline Hyclate | 89 | 23.7 | 23.7 |
| Doxycycline | 89 | 23.4 | 23.5 |
| Mesalamine | 73 | 23.0 | 23.1 |
| Azithromycin Dihydrate | 76 | 23.0 | 23.1 |
| Rosuvastatin Calcium | 36 | 22.0 | 22.0 |
| Budesonide | 66 | 19.7 | 19.8 |
| Naproxen | 86 | 19.6 | 19.6 |
| Ramipril | 101 | 14.8 | 14.8 |
| Naproxen Sodium | 93 | 11.7 | 11.7 |
| Budesonide And Formoterol Fumarate Dihydrate | 61 | 11.0 | 11.0 |
| Tiotropium Bromide | 73 | 9.4 | 9.4 |
| Vismodegib | 4 | 7.5 | 7.5 |
| Ustekinumab | 43 | 7.2 | 7.2 |
| Fingolimod Hcl | 34 | 6.7 | 6.7 |
| Ixekizumab | 13 | 5.9 | 5.9 |
| Siponimod | 3 | 5.6 | 5.6 |
| Ixazomib | 7 | 4.1 | 4.1 |
| Guselkumab | 8 | 3.8 | 3.8 |